Home › Compare › NICXF vs ADC

NICXF vs ADC: Dividend Comparison 2026

NICXF yields 666.67% · ADC yields 4.39%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NICXF wins by $608115.63M in total portfolio value
10 years
NICXF
NICXF
● Live price
666.67%
Share price
$0.30
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$608115.66M
Annual income
$469,561,018,816.25
Full NICXF calculator →
ADC
Agree Realty Corporation
● Live price
4.39%
Share price
$68.40
Annual div
$3.00
5Y div CAGR
5.2%
Payout ratio
73%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.5K
Annual income
$1,093.74
Full ADC calculator →

Portfolio growth — NICXF vs ADC

📍 NICXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNICXFADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NICXF + ADC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
NICXF pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NICXF
Annual income on $10K today (after 15% tax)
$56,666.67/yr
After 10yr DRIP, annual income (after tax)
$399,126,865,993.81/yr
ADC
Annual income on $10K today (after 15% tax)
$372.81/yr
After 10yr DRIP, annual income (after tax)
$929.68/yr
At 15% tax rate, NICXF beats the other by $399,126,865,064.13/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NICXF + ADC for your $10,000?

NICXF: 50%ADC: 50%
100% ADC50/50100% NICXF
Portfolio after 10yr
$304057.84M
Annual income
$234,780,509,954.99/yr
Blended yield
77.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

NICXF
No analyst data
Altman Z
-14.8
Piotroski
3/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+18.5% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NICXF buys
0
ADC buys
0
No recent congressional trades found for NICXF or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNICXFADC
Forward yield666.67% ✓4.39%
Annual dividend / share$2.00$3.00 ✓
Payout ratio50% ✓73%
1-year div growth0%2.8% ✓
5-year div CAGR0%5.2% ✓
Portfolio after 10y$608115.66M ✓$23.5K
Annual income after 10y$469,561,018,816.25 ✓$1,093.74
Total dividends collected$596792.85M ✓$7.4K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: NICXF vs ADC ($10,000, DRIP)

YearNICXF PortfolioNICXF Income/yrADC PortfolioADC Income/yrGap
1← crossover$77,367$66,666.67$10,871$461.40+$66.5K → NICXF
2$564,818$482,035.31$11,824$506.91+$553.0K → NICXF
3$3,893,246$3,288,890.67$12,866$557.16+$3.88M → NICXF
4$25,352,760$21,186,987.16$14,006$612.66+$25.34M → NICXF
5$156,070,781$128,943,327.59$15,254$674.00+$156.06M → NICXF
6$908,837,800$741,842,064.29$16,622$741.82+$908.82M → NICXF
7$5,009,769,782$4,037,313,336.56$18,120$816.86+$5009.75M → NICXF
8$26,159,339,258$20,798,885,591.56$19,763$899.90+$26159.32M → NICXF
9$129,490,317,125$101,499,824,118.87$21,565$991.86+$129490.30M → NICXF
10$608,115,658,140$469,561,018,816.25$23,543$1,093.74+$608115.63M → NICXF

NICXF vs ADC: Complete Analysis 2026

NICXF — Stock

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.

Full NICXF Calculator →

ADC — REIT

Agree Realty is a net-lease REIT focused on high-quality retail tenants including Walmart, Home Depot, and Tractor Supply. Its monthly dividend and focus on investment-grade tenants make it a conservative REIT alternative to Realty Income. Conservative leverage and disciplined acquisition strategy set it apart.

Full ADC Calculator →
📬

Get this NICXF vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NICXF vs SCHDNICXF vs JEPINICXF vs ONICXF vs KONICXF vs MAINNICXF vs NNNNICXF vs EPRTNICXF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.